Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent rotavirus reassortant vaccine
- Development stage
- Unknown
- Lead developer
- Lanzhou Institute of Biological Products
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
The trivalent rotavirus reassortant vaccine is a live-attenuated oral vaccine developed by the Lanzhou Institute of Biological Products (LIBP) for the prevention of rotavirus-induced gastroenteritis in infants and children. It is an evolution of the monovalent Lanzhou Lamb Rotavirus (LLR) vaccine, utilizing the lamb rotavirus strain (G10P[15]) as a genetic backbone. Through reassortment, the vaccine incorporates human rotavirus VP7 surface proteins from serotypes G2, G3, and G4. This multivalent approach is designed to provide broader protective immunity against the most prevalent circulating rotavirus serotypes in China compared to the original monovalent formulation. The vaccine was approved by the National Medical Products Administration (NMPA) of China to reduce the incidence and severity of diarrhea caused by rotavirus infections.
- Brand names
- 瑞特威
- Other names
- Trivalent live human-lamb rotavirus reassortant vaccineLLR-multivalent rotavirus vaccineTrivalent live rotavirus vaccine
02
Targets
VP7 (Rotavirus A VP7 surface glycoprotein)VP4 (Rotavirus VP4)HBGAs (Histo-blood group antigens and cell surface glycans)
Beyond the preview
Go deeper on trivalent rotavirus reassortant vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent rotavirus reassortant vaccine.